Entero Therapeutics (NASDAQ:GRDX – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
Entero Therapeutics Price Performance
NASDAQ GRDX opened at $3.25 on Friday. Entero Therapeutics has a 1-year low of $1.87 and a 1-year high of $6.93. The business’s fifty day moving average price is $4.29 and its 200-day moving average price is $3.61.
Entero Therapeutics (NASDAQ:GRDX – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.27) earnings per share (EPS) for the quarter. The business had revenue of $0.04 million during the quarter.
Entero Therapeutics Company Profile
Entero Therapeutics is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its research has focused on therapies designed to act in the digestive tract, including candidates for celiac disease, inflammatory bowel disease and exocrine pancreatic insufficiency. Its pipeline has included latiglutenase, an oral enzyme therapy intended to break down gluten in the gut, and adrulipase, an oral enzyme replacement candidate for people with exocrine pancreatic insufficiency.
Recommended Stories
- Five stocks we like better than Entero Therapeutics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
